Elevate Imaging, Inc. appears in FDA's public 510(k) records as the applicant for a single submission, K260454, for a device named LiLi DICOM Viewer (LiLi). The record lists a Traditional 510(k) received February 11, 2026, decided November 4, 2026 as substantially equivalent, with a Summary statement and the Radiology advisory committee. The filing address on that record is in Reston, Virginia; that is a filing address, not a verified headquarters. [1][4][5]

The documented clearance and its scope

K260454 covers the LiLi DICOM Viewer (LiLi) under product code LLZ, which FDA's record maps to regulation number 892.2050 and the device name System, Image Processing, Radiological, device class 2, medical specialty Radiology. The decision code is SESE and the decision description reads Substantially Equivalent. The submission is listed as Traditional, with third-party review flagged N and the expedited review flag left blank. [1][4]

Independent trackers that republish openFDA data describe the same single clearance. Arca states that, as of November 18, 2026, FDA's public records list the company with one 510(k) clearance, the most recent dated November 4, 2026 for LiLi DICOM Viewer (LiLi). DeviceClearance likewise reports one clearance, cleared in 2026, under product code LLZ. These are counts of the linked filings at a point in time, not measures of sales or portfolio breadth. [5][8]

A third-party device register lists the same clearance date and marks the firm as registered with US (FDA) while showing no registration with UK (MHRA), Canada (Health Canada), AU (TGA) or EU (EUDAMED). That register's coverage reflects its own sources and refresh schedule. [7]

How the company describes LiLi

The company’s own LiLi page describes LiLi as a cloud-enabled, end-to-end, built-for-purpose technology platform covering the full scope of an imaging trial workflow, connecting the image from acquisition through analysis and tracking progress in real time. The same page frames disconnected technologies as a cause of missing images, frustrated sites and delayed timelines. These are the publisher's characterizations, not independently verified performance claims. [2]

The company’s home page describes a medical imaging service for clinical research that spans strategic protocol design through final data export, with expert review and imaging partners. It lists therapeutic areas, modalities and review criteria. Those descriptions establish the publisher’s stated service scope; they do not independently verify compliance or clinical performance. [3][6]

Applicant identity and what remains unknown

The FDA record names Elevate Imaging, Inc. as applicant, with a contact name and a Reston, Virginia address on the submission. Nothing in the public documents identifies a parent company, subsidiary, brand owner or corporate affiliate, so the applicant should be treated as the regulated entity of record rather than as a verified brand of any larger group. [1][4]

The sources do not establish when LiLi became commercially available, who its customers are, how many trials have used it, or any clinical performance result. The company site's reference to experience across thousands of clinical trials is the publisher's own statement and is not corroborated by the FDA record, which documents one clearance. [1][3]